Despite intensive effort expended in the development of CAIX inhibitors designed to engage only the active site, nuclear imaging analogs have continued to demonstrate limited success, showing < 2% ID/g within tumor and high radiotracer uptake within kidney and liver [21–26]. The gene discussed is CA9; the disease is neoplasm.